Pore-forming toxins (PFTs) are abundant bacterial virulence factors that play a role in infections by numerous problematic pathogens and are potential targets in the search for novel antimicrobial therapeutics. PFTs perforate host cell membranes, allowing bacteria to evade the immune system and spread within the host. Host cells in turn employ defense pathways to survive and repair their cell membranes. Besides disabling PFT function, PFT-targeting strategies may include the priming or boosting of host defenses. Activity and expression of NR4A-family orphan nuclear receptors, which we have identified as novel PFT defense factors, can be manipulated in vitro and in vivo by small compounds. We propose two specific aims directed at elucidating the molecular mechanisms of how NR4As defend against PFTs and intact pathogens using multiple model systems and at applying this new knowledge as a new therapeutic strategy for identifying small compounds to treat and prevent important infectious diseases.

Public Health Relevance

Many bacteria that cause serious infections in humans make pore-forming toxins, which can damage human cells and which are required for infection to occur. In this proposal, we will test new methods for understanding how human cells can be defended against such toxins and will evaluate drug candidates for bolstering such protection. Successful completion of these studies will further the search for new classes of drugs to prevent and treat infectious diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
7R21AI111020-03
Application #
9231663
Study Section
Special Emphasis Panel (ZRG1-IDM-B (80))
Program Officer
Huntley, Clayton C
Project Start
2014-02-01
Project End
2017-01-31
Budget Start
2016-03-01
Budget End
2017-01-31
Support Year
3
Fiscal Year
2015
Total Cost
$194,925
Indirect Cost
$79,925
Name
New York University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Hooven, Thomas A; Catomeris, Andrew J; Bonakdar, Maryam et al. (2018) The Streptococcus agalactiae Stringent Response Enhances Virulence and Persistence in Human Blood. Infect Immun 86:
Rampersaud, Ryan; Lewis, Emma L; LaRocca, Timothy J et al. (2018) Environmental pH modulates inerolysin activity via post-binding blockade. Sci Rep 8:1542
Baker, Jacqueline A; Lewis, Emma L; Byland, Leah M et al. (2017) Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization. Vaccine 35:1273-1280
Joseph, Leroy C; Kokkinaki, Dimitra; Valenti, Mesele-Christina et al. (2017) Inhibition of NADPH oxidase 2 (NOX2) prevents sepsis-induced cardiomyopathy by improving calcium handling and mitochondrial function. JCI Insight 2:
Hooven, Thomas A; Catomeris, Andrew J; Akabas, Leor H et al. (2016) The essential genome of Streptococcus agalactiae. BMC Genomics 17:406
LaRocca, Timothy J; Sosunov, Sergey A; Shakerley, Nicole L et al. (2016) Hyperglycemic Conditions Prime Cells for RIP1-dependent Necroptosis. J Biol Chem 291:13753-61
Amaral, Fábio E; Parker, Dane; Randis, Tara M et al. (2015) Rational manipulation of mRNA folding free energy allows rheostat control of pneumolysin production by Streptococcus pneumoniae. PLoS One 10:e0119823
LaRocca, T J; Stivison, E A; Mal-Sarkar, T et al. (2015) CD59 signaling and membrane pores drive Syk-dependent erythrocyte necroptosis. Cell Death Dis 6:e1773
Hooven, Thomas A; Randis, Tara M; Daugherty, Sean C et al. (2014) Complete Genome Sequence of Streptococcus agalactiae CNCTC 10/84, a Hypervirulent Sequence Type 26 Strain. Genome Announc 2:
LaRocca, Timothy J; Stivison, Elizabeth A; Hod, Eldad A et al. (2014) Human-specific bacterial pore-forming toxins induce programmed necrosis in erythrocytes. MBio 5:e01251-14

Showing the most recent 10 out of 13 publications